How does IgG's structure influence the function of the anti-Rat IgG(HL)-N-MMAF ADC?

The Y-shaped structure of IgG antibodies, featuring two heavy chains and two light chains, allows for multiple binding sites, enhancing the ADC's ability to bind effectively. This structural attribute is crucial for the specificity and efficiency of the ADC in targeting cells expressing rat IgG(H+L).

What specific advantages does the noncleavable linker confer to the anti-Rat IgG(HL)-N-MMAF ADC compared to cleavable linkers?

A noncleavable linker ensures that the cytotoxic payload, MMAF, remains attached to the antibody fragment until the ADC-antigen complex is internalized and degraded within the target cell's lysosome. This minimizes the risk of releasing the cytotoxic agent into the bloodstream, enhancing target-specific cytotoxicity and reducing systemic side effects.

How does the anti-Rat IgG(HL)-N-MMAF ADC contribute to the development of more effective ADCs?

By providing a reliable method for screening the binding efficiency and cytotoxic potential of rat monoclonal antibodies, this ADC helps in identifying and optimizing potent antibodies for therapeutic ADC development, thereby streamlining the early stages of drug discovery.

What methodologies are recommended for quantifying the effectiveness of the anti-Rat IgG(HL)-N-MMAF ADC in lab settings?

Techniques such as flow cytometry, cell viability assays, and confocal microscopy are recommended to assess the binding specificity and cytotoxic effects of the ADC on target cells, providing quantitative and qualitative data on its effectiveness.

What cell types are typically targeted by the anti-Rat IgG(HL)-N-MMAF ADC in research studies?

The ADC targets cells that express or are coated with rat IgG(H+L), which can include a variety of cancer cell lines modified to express this subtype of IgG or cells involved in immune responses where rat IgG is a factor.

Home
Products
Anti-Ab ADCs
IgG (H+L)
anti-Rat IgG(HL)-N-MMAF ADC

anti-Rat IgG(HL)-N-MMAF ADC (CAT#: ADC-AA-045)

This ADC product is comprised of an anti-rat IgG(H+L) specific polyclonal antibody conjugated via a noncleavable linker to MMAF. The antibody portion is a secondary antibody and the drug portion, MMAF, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG(H+L)

Overview
IgG antibody subtype is the most abundant serum immunoglobulins of the immune system, which is a protein complex composed of four peptide chains—two identical heavy chains and two identical light chains arranged in a Y-shape typical of antibody monomers. IgG is secreted by B cells and is found in blood and extracellular fluids and provides protection from infections caused by bacteria, fungi and viruses.

Overview
anti-rat IgG(H+L) specific polyclonal IgG antibody

Species Reactivity
Rat

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
MMAF (Monomethyl auristatin F)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-045. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Excellent quality!

The anti-Rat IgG(HL)-N-MMAF ADC provided consistent and reliable results with strong cytotoxic effects. The product's low toxicity made it perfect for our detailed research work.

Excellent

Highly effective ADC!

This product worked wonderfully in our experiments, offering precise targeting with minimal background interference. The noncleavable linker and MMAF combination proved to be very potent.

Excellent

Highly recommend!

The anti-Rat IgG(HL)-N-MMAF ADC worked flawlessly in our experiments, with excellent specificity and no added toxicity. The quality assurance and prompt delivery were much appreciated.

Excellent

Top-notch product!

The anti-Rat IgG(HL)-N-MMAF ADC delivered reliable results with precise targeting and effective cell death induction. The quality and performance exceeded our expectations.

Excellent

Exceeded expectations!

The anti-Rat IgG(HL)-N-MMAF ADC demonstrated great precision and effectiveness. The cytotoxicity levels were consistent, and the absence of toxicity issues made it a valuable asset.

Q: 1: How does IgG's structure influence the function of the anti-Rat IgG(HL)-N-MMAF ADC?
A: The Y-shaped structure of IgG antibodies, featuring two heavy chains and two light chains, allows for multiple binding sites, enhancing the ADC's ability to bind effectively. This structural attribute is crucial for the specificity and efficiency of the ADC in targeting cells expressing rat IgG(H+L).
Q: 2: What specific advantages does the noncleavable linker confer to the anti-Rat IgG(HL)-N-MMAF ADC compared to cleavable linkers?
A: A noncleavable linker ensures that the cytotoxic payload, MMAF, remains attached to the antibody fragment until the ADC-antigen complex is internalized and degraded within the target cell's lysosome. This minimizes the risk of releasing the cytotoxic agent into the bloodstream, enhancing target-specific cytotoxicity and reducing systemic side effects.
Q: 3: How does the anti-Rat IgG(HL)-N-MMAF ADC contribute to the development of more effective ADCs?
A: By providing a reliable method for screening the binding efficiency and cytotoxic potential of rat monoclonal antibodies, this ADC helps in identifying and optimizing potent antibodies for therapeutic ADC development, thereby streamlining the early stages of drug discovery.
Q: 4: What methodologies are recommended for quantifying the effectiveness of the anti-Rat IgG(HL)-N-MMAF ADC in lab settings?
A: Techniques such as flow cytometry, cell viability assays, and confocal microscopy are recommended to assess the binding specificity and cytotoxic effects of the ADC on target cells, providing quantitative and qualitative data on its effectiveness.
Q: 5: What cell types are typically targeted by the anti-Rat IgG(HL)-N-MMAF ADC in research studies?
A: The ADC targets cells that express or are coated with rat IgG(H+L), which can include a variety of cancer cell lines modified to express this subtype of IgG or cells involved in immune responses where rat IgG is a factor.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-035	anti-RIgG(HL)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-038	anti-RIgG(HL)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-034	anti-RIgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-047	anti-Rat IgG(HL)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-036	anti-RIgG(HL)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)

CAT#	Product Name	Linker	Payload
ADC-AA-015	anti-HIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-008	anti-HIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-019	anti-MIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-W-537	Anti-TPBG-Mc-MMAF ADC	Mc (maleimidocaproyl)	MMAF (Monomethyl auristatin F)
ADC-AA-049	Protein G-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-W-515	Anti-EGFR (ABT-806)-Mc-MMAF ADC	Mc (maleimidocaproyl)	MMAF (Monomethyl auristatin F)
ADC-AA-019	anti-MIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-010	anti-HIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.